Prevagen vs Neuriva: What the Courts Decided About Each One

Prevagen vs Neuriva: What the Courts Decided About Each One

If you are weighing Prevagen vs Neuriva, the short answer is that neither has the memory evidence its advertising implied. A jury found Prevagen's memory claims misleading in February 2024, and a court barred them in December 2024 (the appeal is pending as of September 2026). Neuriva's roughly $8 million class-action settlement was vacated on appeal in April 2023, so no court order restricts its wording today. If you came here to find a winner, this is not a contest between a good option and a bad one.

Key Takeaways

• No winner to crown. Both products have thin evidence for the memory claims on the box, and both have been through federal litigation over those claims.
• Prevagen's one trial missed its primary endpoint. Positive results came from more than 30 unplanned post hoc subgroup analyses.
• Neuriva's settlement was thrown out on appeal. The Eleventh Circuit vacated it in April 2023. No court order restricts the brand's wording today, a fact most comparison pages get wrong.
• "Clinically tested" is not "clinically proven." The difference is legal, not scientific, and understanding it matters more than picking a side.

What Is in Each Product

Prevagen contains apoaequorin, a calcium-binding protein originally from the jellyfish Aequorea victoria, now produced as a recombinant protein. One capsule daily at 10 mg (Regular Strength) or 20 mg (Extra Strength). Some versions add vitamin D.

Neuriva Original contains coffee cherry extract (branded Neurofactor) plus phosphatidylserine. Memory 3D adds B6, B12, folic acid, and Cognicell. The brand's research page describes "over 15 clinical studies" but does not publish doses.

Side-by-Side Evidence Table

Prevagen's Evidence: The Madison Memory Study

Prevagen's maker has published one controlled trial: the Madison Memory Study. It ran from 2009 to 2011, enrolled 218 adults ages 40 to 91 with self-reported memory concerns, and randomized them to 10 mg apoaequorin (n=145) or placebo (n=73) for 90 days across nine Cogstate tasks.

The result: no statistically significant improvement across the full study population. After that failure, researchers ran more than 30 unplanned post hoc subgroup analyses. Two overlapping subgroups showed nominally significant results on a few of nine tasks, but running that many comparisons without correction makes false positives likely -- on the order of an 80 percent chance of at least one, assuming independence across tests. The published paper (2016) had four authors, all Quincy Bioscience employees.

There is also a biological problem. Apoaequorin is a protein. The McGill Office for Science and Society noted that Quincy's own safety data states it "is easily digested by pepsin." The Alzheimer's Drug Discovery Foundation found "strong evidence suggesting that apoaequorin does not survive digestion in the gut or cross the blood-brain barrier."

Neuriva's Evidence: Ingredient Studies, Not Product Studies

Neuriva's marketing says the product is backed by "over 15 clinical studies." That number refers to ingredient-level studies, not studies of the finished product you buy.

Take phosphatidylserine. Trials reporting a cognitive benefit used 300 to 600 mg per day. Review sites and ConsumerLab report Neuriva Original contains 100 mg per serving; the brand does not publish doses. That is a three-to-sixfold gap between the dose studied and the dose sold.

The FDA does allow a qualified health claim for phosphatidylserine, but its required language is revealing: "Very limited and preliminary scientific research suggests that phosphatidylserine may reduce the risk of dementia in the elderly. FDA concludes that there is little scientific evidence supporting this claim." That disclaimer is part of the claim itself.

Neurofactor, the branded coffee cherry extract, is described by the brand as increasing levels of brain-derived neurotrophic factor (BDNF). BDNF is real and involved in neuron maintenance, but a short-term bump in a blood biomarker is not the same as demonstrating improved memory in people over months.

Both products have enthusiastic customer reviews. That is not surprising. Expectation, routine, and the feeling of doing something proactive about your brain are powerful forces in their own right.

"Clinically Tested" Is Not "Clinically Proven"

Prevagen once said "clinically shown to improve memory." Neuriva once said "clinically proven." Neither uses those phrases today.

"Clinically tested" means a study happened. "Clinically proven" means a study succeeded on its primary endpoint by conventional statistical standards. That gap is the space these products occupy.

Prevagen's maker was barred by a federal court from saying the product "can improve memory or cognition" or that it is "clinically proven." Neuriva shifted from "clinically proven" to "clinically tested" during its class-action settlement, but that settlement was vacated. The brand's current language is voluntary, not court-ordered.

Next time you see "clinically tested" on a supplement, ask: tested for what, at what dose, against what comparison, and what happened?

The Legal Record, Side by Side

Prevagen timeline:

• January 2017: FTC and New York Attorney General filed suit against Quincy Bioscience.
• February 2019: Second Circuit reversed a dismissal, returning the case to the district court.
• February 2024: A jury found that claims Prevagen "has been clinically shown to improve memory" and "reduces memory problems associated with aging" were materially misleading.
• December 2024: The court barred Quincy from claiming Prevagen improves memory or cognition, shows results within 90 days, or is "clinically proven."
• February 2026: Second Circuit heard oral arguments. The appeal is pending as of September 2026.

One visible consequence: prevagen.com now calls Prevagen "an over-the-counter supplement for your brain." The word "memory" does not appear on the homepage.

Neuriva timeline:

• 2020-2021: Class actions (Williams v. Reckitt Benckiser) alleged Neuriva's "clinically proven" advertising was false. A roughly $8 million settlement barred "shown" claims while permitting "clinically tested."
• March 2022: Final court approval of the settlement.
• April 2023: The Eleventh Circuit vacated the settlement because the named plaintiffs lacked Article III standing for injunctive relief.

No court-approved settlement is in force against Neuriva today. Every comparison page that says "Neuriva settled and is barred from claiming it works" has been wrong since April 12, 2023.

Cost

Prevagen Extra Strength lists at $59.95 for 30 capsules on the maker's store, roughly $2.00 per day. Neuriva is generally sold for less, though prices vary by version and retailer. Two dollars a day for something that works is fine. A dollar a day for something that does not is a dollar wasted.

Conclusion

If the reason for buying either product is memory improvement, the evidence is thin for both, and the court record says so twice. This is not a reviewer's opinion. It is what a jury found, what a judge ordered, and what an appellate court's vacatur left unresolved.

If you want better odds, the list is boring: consistent sleep, exercise, blood-pressure management, hearing and vision checks, and a conversation with a clinician about medications and B12. The AARP Global Council on Brain Health reviewed the evidence in 2019 and could not endorse any supplement ingredient or formulation for brain health. Dr. Pieter Cohen of Harvard-affiliated Cambridge Health Alliance put it bluntly in Harvard Health: nothing legally contained in supplements has been proven to improve your thinking or prevent memory loss.

That does not mean every ingredient is useless. It means these two have not cleared the bar. For a broader look at what the pharmacy shelf offers, what independent evaluations say, or a wider comparison of brain and memory supplements, the reading is sobering but useful.

Frequently Asked Questions

Which is better, Prevagen or Neuriva?

Neither has strong evidence for the memory claims on its label. Prevagen's trial failed its primary endpoint across the full population, and positive results came from unplanned post hoc analyses. Neuriva cites ingredient-level studies, and its phosphatidylserine dose appears well below what was used in research that reported a benefit. Two federal cases questioned both products' advertising. There is no honest basis for picking a winner.

Is Neuriva backed by clinical studies?

The brand claims "over 15 clinical studies," but these are ingredient-level studies, not studies of the finished product. The doses in those studies may differ from what is in the capsule you buy. "Clinically tested" on the box means a study occurred, not that it demonstrated the specific benefit the marketing implies.

Can you take Prevagen and Neuriva together?

No head-to-head safety data exists for this combination. The ingredients differ (a protein in Prevagen, a phospholipid and plant extract in Neuriva), and neither label addresses concurrent use. Talk to your clinician before combining supplements, especially if you take prescription medications.

Why is Prevagen still sold if the FTC won?

The court barred specific advertising claims, not the sale of the product. Prevagen remains a legal dietary supplement. What changed is how it can be marketed: Quincy Bioscience was ordered to stop saying Prevagen improves memory or cognition, or that it is "clinically proven." The appeal is pending as of September 2026.

Was Neuriva sued, and what happened?

Yes. A roughly $8 million class-action settlement was reached and approved in 2022, alleging "clinically proven" advertising was false. But the Eleventh Circuit vacated that approval in April 2023 because the plaintiffs lacked standing for injunctive relief. No court order restricts Neuriva's wording today. The brand's use of "clinically tested" rather than "clinically proven" is voluntary, not legally required.

What does "clinically tested" actually mean on a supplement box?

It means a clinical study was conducted on the product or one of its ingredients. It does not mean the study found a benefit, that it was large or well-designed, or that an independent body reviewed the results. Under FDA supplement regulations, companies are responsible for the accuracy of their own claims. "Clinically tested" is not equivalent to "FDA-approved" or "clinically proven."

Final Word

Neither Prevagen nor Neuriva has cleared the evidence bar for memory improvement. The best-supported strategies remain sleep, exercise, and a conversation with your clinician.

Neither Memory Supplement Answers the 3 p.m. Focus Question

Both Prevagen and Neuriva are positioned as daily memory and cognitive-health products, and for people pursuing that goal over weeks or months, the choice comes down to ingredient preference and tolerance for evidentiary gaps. That is a legitimate category even if neither product has cleared a high clinical bar.

But if the real problem is holding attention through a four-hour work block this afternoon, you are asking a different question. Roon is a zero sugar sublingual caffeine pouch (80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine, 5 mg theacrine) engineered for acute alertness across a 6 to 8 hour window. It makes no memory claim, and its 80 mg caffeine sits below the doses used in caffeine-and-memory research. Stop at least 8 hours before bed. Subscriptions start from $9.16 per tin, or as little as $0.61 per pouch; a one-time 4-tin order is $15.00 per tin.

Long-term brain health still belongs with sleep, exercise, and a clinician. Roon is just the boring, legal stimulant for the task in front of you.

Written by Roon Team